Olema Pharmaceuticals, Inc.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals announced the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026. As part of the appointment, O'Byrne received an employment inducement award of 650,000 stock options with an exercise price of $10.56 per share, vesting over four years with 25% vesting after one year and the remainder vesting monthly over three years.